+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 23 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating patient satisfaction, effectiveness, and safety of the drug Atezolizumab given by subcutaneous injection in people treated for certain cancers in routine healthcare settings. This observational study includes participants with specific types of lung cancer and hepatocellular carcinoma who receive Atezolizumab according to approved indications without altering their usual treatment plans. Participants are grouped into cohorts based on their diagnosis, including early-stage non-small cell lung cancer NSCLC after surgery and chemotherapy, metastatic NSCLC, extensive-stage small cell lung cancer ES-SCLC, and advanced or unresectable hepatocellular carcinoma HCC. The treatment with Atezolizumab is administered by the participants doctor independently of study participation. Throughout the study, participants report their satisfaction with the subcutaneous therapy using questionnaires at specific treatment cycles, and their quality of life is assessed by standardized tools. Researchers monitor survival outcomes and adverse events for up to approximately 3.5 years. The study captures real-world data on treatment experiences and monitors safety and effectiveness during routine clinical care.

Age: 18Years +All Genders
92 locations
S

Actively Recruiting

Healthy Volunteer

The WILLEM study is a multicenter observational trial focusing on high-risk cardiac patients with arrhythmias or abnormal ECG patterns. It aims to validate a cloud-based AI-powered ECG analysis platform called Willem173, which is designed to detect and predict cardiac abnormalities. The study compares the AI diagnoses with cardiologists evaluations and assesses the platforms ability to delay or avoid severe cardiac events such as sudden death. Participants include patients with relevant cardiac arrhythmias or diseases and at least one ECG record with over one year of follow-up data. Participants are divided into two groups a training group to develop new AI methodologies and a test group to evaluate the AIs performance and avoid overfitting. The AI platform analyzes cardiac electrical signals lasting 10 seconds or more, collected from various devices including hospital ECG machines, Holter monitors, wearable ECG patches, and telemedicine interfaces. Cardiology experts review all data to label arrhythmias and patterns. Both retrospective and prospective patient data are used. During the study, participants provide ECG data and clinical information for analysis. Researchers monitor primary outcomes such as real-time detection of cardiac arrhythmias within minutes of ECG recording. Secondary outcomes include survival, major cardiovascular events, rehospitalization, and quality of life measured one year after the initial ECG or enrollment. Informed consent is obtained from patients or authorized relatives if patients cannot consent themselves. The study is conducted until November 2026, with ongoing data collection and evaluation.

Age: 4Years +All Genders
13 locations
S

Actively Recruiting

Researchers are evaluating a new approach to prevent heart and blood vessel problems in patients with inflammatory rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and systemic lupus erythematosus. These patients have a 50% higher chance of cardiovascular events compared to the general population, and current risk scores often underestimate their true risk. This phase IV clinical trial aims to test if using carotid ultrasound to detect early artery disease can better identify patients at high risk and improve prevention. Participants aged 50 years and older with inflammatory rheumatic diseases and low-to-moderate cardiovascular risk will be randomly assigned to either receive a carotid ultrasound or follow standard care based on current guidelines. Those in the ultrasound group found to have carotid plaques will be classified as very high risk and started on high-intensity statin therapy to lower LDL cholesterol below 55 mgdL. Patients without plaques and those in the control group will receive care according to the European Society of Cardiology 2021 recommendations. The study will last 48 months with ongoing monitoring. Throughout the study, patients will have regular visits to track their health and treatment effects. Those needing lipid-lowering therapy will have monthly visits during treatment adjustment, then every six months until the study ends. All patients will be monitored for major cardiovascular events such as heart attacks, strokes, and hospitalizations over four years. Safety and side effects will also be evaluated, aiming to see if the ultrasound-based strategy better prevents heart problems compared to standard care.

Age: 50Years +All GendersPhase 4
17 locations
P

Actively Recruiting

Researchers are evaluating whether adding Hyperthermic Intraperitoneal Chemotherapy HIPEC with Mitomycin C after complete surgical removal of peritoneal metastases in patients with colon cancer affects the chance of cancer returning in the abdomen. This phase IV clinical trial addresses uncertainties from prior research by focusing on the time patients remain free from peritoneal recurrence rather than overall survival. It excludes rectal cancers and patients with extensive peritoneal disease or incomplete surgery to better understand HIPECs role in this setting. Participants are randomly assigned to one of two groups one receiving complete cytoreductive surgery plus HIPEC with Mitomycin C delivered at 35 mgm2 in a heated peritoneal dialysis solution for 90 minutes with dose fractionation, and the other receiving surgery alone without HIPEC. The study corrects previous trial shortcomings by increasing HIPEC infusion time and limiting patient selection based on cancer spread and surgery completeness. During the trial, participants will be monitored for peritoneal recurrence over three years, with assessments including imaging and disease-free survival measures. Researchers will also track postoperative complications within 90 days after surgery and evaluate quality of life at multiple points before surgery, after chemotherapy, and at one and two years. The trial aims to provide detailed information on recurrence patterns, survival, and patient well-being over three years following treatment.

Age: 18Years +All GendersPhase 4
31 locations
P

Actively Recruiting

Researchers are conducting a multicenter, double-blind, placebo-controlled Phase III clinical trial to evaluate inhaled aprotinin in adults with moderate or severe acute respiratory distress syndrome ARDS. ARDS is a serious lung condition causing inflammation, fluid buildup, and severe breathing failure. Despite current supportive care, no specific drug treatment has shown clear benefit, so this study aims to assess if inhaled aprotinin can improve patient outcomes. In this trial, 156 critically ill patients in intensive care units will be randomly assigned to receive either inhaled aprotinin or a placebo, alongside standard supportive treatments. Aprotinin will be given by nebulization through breathing tubes, four times daily at a dose of 500 KIU every six hours for six days. The placebo group will follow an identical schedule. The study uses a double-blind design to keep participants and researchers unaware of group assignments. Participants will be closely monitored during their ICU and hospital stay with regular assessments of breathing, organ function, and inflammation markers. The main measurement is the number of days patients are free from mechanical ventilation within 28 days after treatment starts. Secondary outcomes include survival rates, time spent in ICU or hospital, kidney and heart support needs, and biomarker levels. Safety will be overseen by an independent committee, and follow-up will continue up to 180 days after treatment.

Age: 18Years +All GendersPhase 3
1 location
C

Actively Recruiting

Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.

All AgesAll Genders
305 locations
P

Actively Recruiting

Researchers are conducting an international, multicenter, prospective, non-randomized observational study to confirm and support the clinical safety and performance of the Coroflex ISAR NEO coronary stent system. This study focuses on patients with coronary artery disease CAD or ischemic heart disease treated in real-world clinical settings to meet European Union Medical Device Regulation requirements for post-market follow-up. It involves consecutive patients treated with the sirolimus-eluting Coroflex ISAR NEO stent as intended by the manufacturer. Participants receive the Coroflex ISAR NEO coronary stent system during their routine percutaneous coronary intervention PCI procedures. This study observes patients undergoing stent placement according to standard clinical recommendations, without randomization or specific treatment assignment. The study includes patients with new lesion lengths between 2 and 4 mm and follows them after stent implantation to monitor outcomes and device performance. During the study, participants are monitored for safety and effectiveness outcomes including freedom from target lesion failure within seven days after the procedure. Additional assessments track potential complications during PCI such as accidental stent dislodgement, balloon or hypotube rupture, coronary perforation, dissection, no reflow, and thrombosis. Data collection continues according to clinical practice, with informed consent obtained and follow-up lasting up to the study completion date in February 2027.

Age: 18Years +All Genders
26 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness and safety of subcutaneous immunotherapy in patients aged 12 to 65 who have mild to moderate rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma, caused by sensitivity to grass and olive pollen. This randomized, double-blind, placebo-controlled phase 3 trial aims to study allergy treatments to improve symptoms and reduce medication use over one year. Participants are randomly assigned to one of three groups one receiving 10,000 TUmL MG01 plus 10,000 TUmL T517, another receiving 30,000 TUmL MG01 plus 10,000 TUmL T517, and a placebo group receiving the same solution without active ingredients. The allergen extracts come from a mixture of grasses and olive pollen, administered through subcutaneous injections. Treatment lasts for one year, evaluating different doses compared to placebo. During the study, participants will regularly record symptoms and medication use using a smartphone app. Researchers will monitor combined symptoms and medication scores as the primary outcome, along with medication-free days, symptom-free days, asthma exacerbations, quality of life tests for rhinitis and asthma, and immune response measures. Safety is closely followed through adverse reaction monitoring and immunological and security parameters over the 12-month treatment period.

Age: 12Years - 65YearsAll GendersPhase 3
32 locations
G

Actively Recruiting

Researchers are conducting a multicenter observational study to explore the genetic factors and clinical outcomes in patients with arrhythmia-induced cardiomyopathy AiC. The study focuses on whether patients with AiC have a higher rate of genetic mutations compared to other cardiomyopathy types or the general population, and whether these genetic factors influence prognosis. Participants are those suspected of AiC based on a lower left ventricular ejection fraction without other clear causes, undergoing rhythm control procedures. Participants will be followed for one year after receiving rhythm control treatments such as electric cardioversion or catheter ablation. During this period, genetic testing will be performed to detect variants in cardiomyopathy-related genes. Follow-up visits are scheduled at 2, 6, and 12 months, including electrocardiogram and echocardiography to assess heart function and remodeling. AiC confirmation will depend on improvements in left ventricular ejection fraction during follow-up. Throughout the study, participants will have clinical evaluations and imaging tests to monitor heart function and rhythm control status. Researchers will analyze the prevalence of genetic mutations and track cardiovascular events like heart failure admissions and arrhythmia recurrences. Cardiac remodeling will be assessed by changes in ventricular and atrial parameters. Follow-up care will follow routine clinical practice at each center.

Age: 18Years +All Genders
4 locations
S

Actively Recruiting

Researchers are observing the use of the Ultimaster Nagomi stent in treating coronary artery disease, focusing on its safety and performance in real-world settings. This post-market clinical follow-up study aims to reaffirm the devices effectiveness and safety claims without comparing it to other treatments. Participants treated with the Ultimaster Nagomi drug-eluting stent DES will be followed according to standard hospital practice. The study includes patients with long coronary lesions suitable for a one-stent approach, and all treated lesions are intended to receive this stent. No comparator group is involved as the study observes routine clinical use. During the study, participants undergo assessments including angina status using the Seattle Angina Questionnaire and quality of life via the EuroQol five-dimensional questionnaire at baseline and 12 months. Researchers will track device and procedure safety, performance in complex lesions, and clinical outcomes like target lesion failure, cardiovascular death, and myocardial infarction over one year. The total study duration extends until 2029, with ongoing data collection and monitoring.

Age: 18Years +All Genders
10 locations

1-10 of 23

1